Skip to main content
WST logo

WST · West Pharmaceutical Services Inc · Documents

Track WST — free
Market Cap
$29.01B
Shares
69.66M
Volume · Nov 16 84.42K Avg daily vol (3M) 601.93K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $3.07B up 6.3% 10-K filed Feb 17, 2026 Quarterly report FY2026 Q3 Revenue $874.5M up 8.7% 10-Q filed Oct 29, 2026 Latest results Financial results 8-K filed Oct 29, 2026 Earnings call Q3 2026 earnings call Held Oct 29, 2026
2026
Oct 29
Earnings call
Strong quarter drives raised revenue and EPS guidance

West Pharmaceutical Services raised 2026 revenue guidance to $3.41 to $3.42 billion and adjusted EPS guidance to $9.38 to $9.48, after Q3 revenue of $874 million and adjusted EPS of $2.66.

4 source passages
Welcome to the Q3 2026 West Pharmaceutical Services Earnings Conference call. Revenues of $874 million grew 12% organically, and adjusted EPS of $2.66 was up 36% compared to last year. We now anticipate full-year revenue to be in the range of $3.41 to $3.42 billion, up from a prior range of $3.345 billion to $3.38 billion. Full year 2026 adjusted EPS is expected to be in the range of $9.38 to $9.48, up from A prior range of $8.85 to $9.05. Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

West Pharmaceutical Services Inc reported nine-month 2026 net sales of $2,591.7 million, up 14.2%, and operating profit of $623.6 million, up 45.6%; Proprietary Products drove growth, while West Vantage organic sales declined 0.2%.

Revenue $874.5M ▲ 8.7% Net income $214M ▲ 52.9% Diluted EPS $3.02 ▲ 57.3%
Read from the MD&A section
Oct 29
Current report 8-K
Financial results, Regulation FD disclosure

West Pharmaceutical Services, Inc. reported third-quarter net sales of $874.5 million, up 8.7%, and adjusted-diluted EPS of $2.66, up 35.7%. It raised full-year 2026 net sales guidance to $3.41 billion to $3.42 billion and adjusted-diluted EPS guidance to $9.38 to $9.48.

Read from the first part of this long document
Jul 23
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $872.3M ▲ 13.8% Net income $154M ▲ 16.8% Diluted EPS $2.15 ▲ 18.1%
Apr 23
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $844.9M ▲ 21.0% Net income $138.8M ▲ 54.6% Diluted EPS $1.92 ▲ 56.1%
Mar 12
Proxy statement DEF 14A Meeting May 4, 2026
Proxy statement AI summary on its way
Feb 17
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $3.07B ▲ 6.3% Net income $493.7M ▲ 0.2% Diluted EPS $6.79 ▲ 1.5%
2025
Oct 23
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $804.6M ▲ 7.7% Net income $140M ▲ 2.9% Diluted EPS $1.92 ▲ 3.8%
Jul 24
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $766.5M ▲ 9.2% Net income $131.8M ▲ 18.4% Diluted EPS $1.82 ▲ 20.5%
Apr 24
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $698M ▲ 0.4% Net income $89.8M ▼ 22.1% Diluted EPS $1.23 ▼ 20.6%
Feb 18
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $2.89B ▼ 1.9% Net income $492.7M ▼ 17.0% Diluted EPS $6.69 ▼ 15.1%
2024
Showing 1–50 of 146 documents
Key facts CIK 105770 CUSIP 955306105 13F (30d) 681 filings 624 filers Visit website Investor relations